Furukawa K, Mori M, Ohta N, Ikeda H, Shida H, Furukawa K, Shiku H
Department of Oncology, Nagasaki University School of Medicine, Japan.
J Clin Invest. 1994 Nov;94(5):1830-9. doi: 10.1172/JCI117532.
Short-term culture of peripheral blood mononuclear cells (PBMC) derived from patients with human T cell lymphotropic virus type I-associated myelopathy (HAM)/tropical spastic paraparesis resulted in dominance by DR+ activated CD8+ T cells. Variations in the T cell receptor (TCR) V alpha and V beta chains in these cells were analyzed, and in all 10 patients examined, 2-3 V gene families were dominant in both TCR V alpha and V beta. In five patients we examined, cultured lymphocytes contained cytotoxic lymphocytes for p40tax (patients HAM2, 3, 7, and 8) or env protein (patient HAM4) of human T lymphotropic virus type I. In patients HAM2 and HAM8, cultured lymphocytes contained a large proportion of V beta 8+ CD8+ and/or V beta 12+ CD8+ cells. The sequence of V beta 8+ and V beta 12+ cDNA revealed that they were oligoclonal with identical or similar sequences in each patient. Elimination experiments with monoclonal antibodies for TCR V beta 8 and V beta 12 showed that they were CD8+ cytotoxic T lymphocytes (CTL) for p40tax. In addition, flow cytometry and sequencing analysis of uncultured PBMC revealed that in HAM2, V beta 8+ CTL and their precursors account for 7% and V beta 12+ CTL and their precursors account for 18% of total CD8+ cells. This indicates the presence of two markedly expanded clones in vivo. No common dominant TCR V alpha or V beta were observed among 10 HAM patients analyzed.
对来自I型人类嗜T细胞病毒相关脊髓病(HAM)/热带痉挛性截瘫患者的外周血单个核细胞(PBMC)进行短期培养,结果显示DR + 活化的CD8 + T细胞占优势。分析了这些细胞中T细胞受体(TCR)Vα和Vβ链的变异情况,在所有检测的10例患者中,2 - 3个V基因家族在TCR Vα和Vβ中均占主导地位。在我们检测的5例患者中,培养的淋巴细胞含有针对I型人类嗜T细胞病毒p40tax(患者HAM2、3、7和8)或env蛋白(患者HAM4)的细胞毒性淋巴细胞。在患者HAM2和HAM8中,培养的淋巴细胞含有很大比例的Vβ8 + CD8 + 和/或Vβ12 + CD8 + 细胞。Vβ8 + 和Vβ12 + cDNA的序列显示,它们在每个患者中都是寡克隆的,具有相同或相似的序列。用针对TCR Vβ8和Vβ12的单克隆抗体进行的消除实验表明,它们是针对p40tax的CD8 + 细胞毒性T淋巴细胞(CTL)。此外,对未培养的PBMC进行流式细胞术和测序分析发现,在HAM2中,Vβ8 + CTL及其前体占总CD8 + 细胞的7%,Vβ12 + CTL及其前体占18%。这表明体内存在两个明显扩增的克隆。在分析的10例HAM患者中未观察到共同的优势TCR Vα或Vβ。